> The patient received 5 g of orally administered psilocybin-containing mushrooms
> Approximately 19 h post-administration, spontaneous autobiographical speech emerged. Over subsequent days and weeks, functional improvements included restoration of urinary continence, improved ambulation, autonomous dressing, increased emotional responsiveness, sustained social interaction, contextual memory retrieval, preserved working memory for social context, and spontaneous conversational engagement.
This is exactly that, a treatment using psilocybin that was successful. It's not claiming to have developed a treatment protocol, the title is precise.
That said, some relevant context here is that:
(1) Case studies are some of the most easily fabricated journal outputs
(2) This is published in Frontiers in Neuroscience, which is listed by some as being a predatory journal [0]. The Frontiers publishers are the fine folk who published an AI generated anatomical figure of a rat that not only was obviously incorrect to anyone you'd stop on the street, it'd give them nightmares [1].
So I'm not saying this paper is bunk, but that I reserve a healthy degree of skepticism pending some clinical trials or replication in animal models.
[0] https://www.predatoryjournals.org/news/list-of-all-frontiers...
[1] https://arstechnica.com/science/2024/02/scientists-aghast-at...
Even more interesting, Dr. Radin discussed one of his companies is working on a new drug that uses the same brain receptors as psilocybin, that has the potential to induce similar effects (with no psychedelic side effects) with a nasal delivery system that crosses directly into the brain. The benefit of that, he says, is the effect would last for much longer, months perhaps, and patients would only have to take it a few times per year.
If this is a real phenomenon, then it's amazing to think that at least some of the people who suffer from Alzheimer's still have their memories inside their minds, as opposed to the disease erasing the memories from existence, which means that an effective treatment might recover their identities.
Meanwhile fentanyl is Schedule II. The government is often the biggest barrier to psilocybin research despite its positive effects being acknowledged for decades. Depending on the administration (which will sometimes signal they won't actually enforce the law) these research efforts are often terminated, meaning it is often safer/cheaper to just never start them in the first place.
https://www.dea.gov/drug-information/drug-scheduling
https://www.nature.com/articles/nrn3530
https://www.cato.org/blog/trumps-psychedelic-order-speeds-re...
Questions linger about the long term use; what happens to someone who has been taking this dose, say, every two weeks for a year, or five years? Does even the second dose work as well as the first?
It’s a case report (n=1) that a group of 3 people from Brazil wrote up and pushed into the publishing world. The report is full of big words and tables, but barely says anything more than the abstract: It’s basically “an 80 year old Japanese women received mushrooms and was better afterward” expanded with as much medical jargon as they could apply without accidentally getting too specific. No mention of how the Alzheimer’s disease history was documented or diagnosed or even if she was a patient of one of the authors.
I’m surprised how much it’s getting people to let their guard down and accept the result. Normally when studies get posted with only 100 to 500 participants the comments everywhere are full of doubters calling out the small sample size. For some reason this n=1 story written vaguely about extraordinary claims with a complete absence of pre-treatment documentation or standardize testing/scoring hits all the right notes to convince a lot of people that mushrooms can reverse Alzheimer’s disease.
I know it’s something that a lot of people would like to be true, but this is a domain where anyone in the world can make any claims they want and find a journal who will publish it if you pay them. People write and publish papers like this all the time claiming to have treated major diseases in a single patient or group of patients with different drugs or herbs.
> pay to publish journal
> no clear Alzheimers diagnosis ("[...] were considered clinically most compatible with advanced Alzheimer’s disease")
> administration of a heroic dose of street-quality drugs vs. a controlled sample
> no university or hospital affiliation?
Extraordinary claims require extraordinary evidence, hence I remain skeptical
> This case documents transient multidomain functional improvement in advanced Alzheimer’s disease following psilocybin administration. The findings do not imply disease reversal but suggest that residual functional capacity may persist in late-stage neurodegeneration and may become transiently accessible under specific neuromodulatory conditions.
Very interesting nonetheless.
> One month after the initial session, the patient remained continent and functionally improved compared with baseline. A second supervised psilocybin session using 3 g was subsequently performed and was associated with greater verbal expressivity, improved facial mimicry, spontaneous humor, emotionally valenced autobiographical imagery, and increased agility while walking.
> The patient spontaneously stated: “It is pleasant to come here.
This is just wonderful.
I'm glad that psilocybin research is picking up. I really think its potential benefits deserve to be more widely known and available. Hopefully without the spontaneously appearing dysfunction though
> Generative AI statement
> The author(s) declared that Generative AI was not used in the creation of this manuscript.
> Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Which is good.
But it makes me wonder about “wherever possible”. In which case wouldn’t it be possible and why would it remain if it’s not possible?
edits: formatting
I'm not saying that Frontiers in Neuroscience is not predatory, but its not a proper argument for it to be predatory, to point to a random list as proof. As Beall couldn't understand being crap publisher is not predatory in it self.
That, or individuals will science on the ones they care for. I for one would write something like that down if I were to start developing dementia/alzheimers.
Example of a shop which describes 5g as a "light dose": https://www.sirius.nl/atlantis/
On the other hand, it’s interesting and perhaps illuminating to people working in that field. A field mind you, that has made a little to no progress in decades. Arguments could be made they’ve made some errors and went down the wrong path. It’s a field that could probably use some new ideas.
On the other hand I heard a single dose does permanently increase your trait openness by a standard deviation, which is nuts. So maybe there is causation there too.
Not that I doubt the benefit of a non-psychoactive treatment. Just the adjacency of this idea to Rogan makes me immediately suspicious.
And it’s not even suggestive of eg making an actual medicine that could be taken long term, because Alzheimer’s physically destroys your brain. The restorative effect of psychedelics is just a bandage over not understanding why that damage is happening in the first place.
This would be pretty amazing.
Especially with the effects being temporary - can you imagine how awful it must be to regain lucidity outside of your control and then lose it again for the sake of an experiment like this? Awful experiment.
It isn't a monotonic decline with memories disappearing forever. It is like wave upon wave of changing capacity at different time scales. The general trend is deterioration, but there are frequent periods that can almost seem like remission.
There is a well known daily cycle referred to as "sundowning", where the sufferer tends to come unraveled later in the day. The next morning, they'll be more functional.
Later in the progression, you can see much higher frequency variations. Like periods of disorientation and confusion interspersed with periods of lucidity all within a single sitting or conversation.
In those periods of greater lucidity, recall of the past can be more accurate. General listening comprehension, speaking, and logical thought also seem more normal.
Edit to add: I sometimes wonder if the belief in terminal lucidity is one of those logical fallacies which support lots of superstitions. Are we just fixating on the final wave in this chaotic wave train, and forgetting all the other waves that happened before it? Or is it that more caretakers are engaged and observing these waves towards the end, e.g. because the patient is known to be in the terminal phase..?
As far as ethics go, I would absolutely sign a document that gives the right for experimentation in the event I become incapacitated to some degree.
I'm nobody but it makes me feels there's an economic system issue, the body gradually degrades but has the ability one last time to inject a final wave of change to try restore a proper state but the resources are too short and so the attempt cannot sustain itself.
I wonder if research is happening on this aspect.
I responded to your other comment with this exact text, but to repeat:
This paper is not illuminating to people in the field. This is 3 unaffiliated people who paid to publish an anecdote without any supporting evidence. Paid medical journals are full of these.
Medical professionals know how to spot these claims because they’ve seen a hundred of them over the years that went nowhere. This was published not for the medical establishment, but for news media and social media and maybe to boost the author’s visibility to get funding for something they want to do.
I recently lost a family member to cancer, and had to go through this conspiracy bullshit from evil pieces of shit peddling snake oil to desprate people. Whatever rabbit holes your social media algorithms have led you down aren't healthy, friend. Clear your cookies and go touch grass.
Can’t the President directly unschedule it?
People in medicine or research have seen hundreds of extraordinary case reports like this. They’re everywhere on different topics and they’re not hard to get published.
They know that extraordinary claims require extraordinary evidence and it’s easy to see that this paper is completely devoid of evidence, just some extraordinary claims written in formal medical language, minus the usual process, methodology, and assessments one would expect in a paper like this.
He talked about how his whole career he just followed whatever was most interesting to him at the time, hence the different disciplines. He also talked about programs he ran at universities where he was in charge of bringing different disciplines together & the challenges of that since academia is incredibly siloed. Departments don’t talk to each other.
So I think people like him are very valuable, since they aren’t afraid to think it if the box, work on taboo subjects like “psychic” abilities, and see the universe in novel ways.
He mentioned they’ve done trials in mice and chimpanzees with very positive results. I’m not saying it’s some crazy breakthrough or anything, but it’s interesting and something worth keeping an eye on. It sounded also like the killer feature is the nasal delivery tech. I don’t think the are the first ones to study non psychoactive psilocybin like compounds, but the nasal delivery that can cross into the brain directly seemed important.
Very curious exactly who made the decision/gave permission to take granny on a shroom trip.
I'm not sure I'd trust this person for anything related to science.
I would imagine the losing it again part is typically somewhat similar to how someone remembers a surgery under anesthesia -- they don't.
Last time I visited my grandpa he was really far gone. The day we arrived and subsequent two days he didn't even recognize his daughter, my mom, or even recall he had one. He'd sit in the bedroom and watch the garden, and ask "who's that guy" every 15 minutes or so, as he'd forget about me in the livingroom.
The last day we visited before flying home. I entered first, and this time he sat in the living room, and as he saw me enter the hallway he exclaimed my name. We reminisced for hours in fluent English, his third language and my second language, as I wasn't so good in his and my moms native language. He recalled lots of details, some even I had forgotten but I confirmed later.
He passed away a couple of weeks later.
If you are to believe the Brave New World (https://en.wikipedia.org/wiki/Brave_New_World) worldview of Huxley (who topically was on loads of LSD himself), you'd think the government would want to flood the public with psychedelics -- low to zero toxicity, allows people to zone out, not addictive, allows people to focus inwards rather than focus on civic mismanagement.
Any ideas on why the US government is so opposed Psychedelics? Clearly the government is for Bread and circus. In fact, the establishment left and right want desperately for us to believe everything is indeed fine regardless of the facts our eyes see (e.g. Annie Lowrey on https://www.theatlantic.com/ideas/2026/05/americans-depresse...)
There is a growing tension between the extraordinary pop culture claims of psilocybin curing everything (now extending to Alzheimer’s due to this 1 low-quality report from Brazil) and the actual studied effects, though. A lot of the published outcomes are surprisingly low quality, like this case report or all of the studies that neglect to include a control group. Mental health studies without a control group are basically useless because even a control group that doesn’t receive a placebo (that is, people you simply monitor and interact with) will get better.
Just look at this comment section: People raising suspicions about the obvious problems in the study are being downvoted. The top voted comments are citing a Joe Rogan podcast with a guy hyping his startup. People really, really want to believe this is a magic cure and the usual guardrails of suspicion for extraordinary claims are seemingly suspended for this one topic.
If you've never read a Pulitzer Prize Winner, Confederacy of Dunces would be a personally-relatable disaster (to start with; it's great).
>Psychedelics are one of my favorite classes of drug.
Your initial description of usage was probably a bit wreckless, but I do maintain that most people would probably benefit from a single (or few) psilocybin experiences (preferably an initial high-dosage with a well-trained sitter).
Microdosing is a fantastic long-term strategy, before starting more-prescribed methodologies towards happiness. Probably not useful without an initial high-dosage, first (or much cloudier/ineffective).
YMMV £¢¢£
Keep the pathetic "pat me on the back" comments to Reddit please.
I'm sure it's a little different for everyone though.
Walked out the door one day said "See you later grandma" and she said "Have fun ______" and called me by my real name, called my older siblings and said go spend time, she died two days later.
Very common.
Psyches basically raise the "temperature" (in machine learning parlance) of the brain, increasing crosstalk. This can jostle folks out of a mental rut. But it can also create positive feedback loops of upheaval.
Soma would only work as it did in BNW if society controlled essentially all sources of information - which is essentially the whole premise.
Honest question, does a control group really matter that much when it's not possible to do a blinded study? Unless it's some incredibly small microdose, I would assume most study participants are able to tell if they're tripping or not.
That's the playbook that got marijuana (more or less) legalized. So of course they're going to use the same exact strategy with each drug in turn.
The more biological effects I agreed are not conclusion that can be drawn from that.
Dismissing this "study" (really a case file) because of the N=1 and the shady journal seems like a stronger position than bringing in Rogan. Talking about Rogan just looks like partisan posturing.
I used to be able to swallow gummy bears whole for fun. Or any medication, even huge pills (1g magnesium glycinate, for example -- those pills are not small) -- I didn't even need water. Now, even with water it's hard to swallow any medication, and it's hard to even swallow food half the time. Something definitely went wrong and is now wrong, compared to before.
like idk, how do you do double blind studies of astronomical phenomena?
To be fair, this is not how medical research is done.
So it would actually be very surprising if it was just a clear net positive overall
Our ability to synthesize new compounds has also exploded since then. Drug companies are looking for the next blockbuster drug. They don’t need to use psilocybin. We can now use powerful computers to come up with countless variations of drugs that activate the receptors involve and study them rapidly. There are hundreds of ligands that interact with the same receptors.
One weird trick to try is a "heel drop": https://www.modernapothecary.org/blog/the-healing-power-of-h... Even if you don't have a hernia, it can't hurt to try it; you can even do it accidentally by drinking a sports drink and then jogging around the block. I was shocked to find it ended an awful bout of laryngopharyngeal reflux. (I had a scan long ago that incidentally observed a sliding hiatal hernia, but I didn't have symptoms for many years.)
In any event, I'm sorry you're having this trouble, and I hope it resolves itself.
It's also true that people in the psychedelic world talk about non-reproducible aspects of the trip quite a bit. "Set and setting" and so forth.
Shhh, non-scientists don't know that.
It's great if we have therapies that help people and get a proper scientific stamp. Yet we can also discover the benefits for ourselves before that stamp is given.
Except the ligands matter, binding site is massively important to drug design. As is the behavior of the molecule beyond that. A 5HT2A agonist that's also an irreversible and potent dopamine agonist is obviously a non-starter. Minor modifications of a molecule produce wildly different and very unpredictable effects. Pharmacodynamics and pharmacokinetics are the bottleneck of drug research, and they take quite a lot of work to understand.
> We can now use powerful computers to come up with countless variations of drugs that activate the receptors involve and study them rapidly.
"Research chemical" is common parlance, and it's synonymous with "dangerous gutter drug" because you end up with nasty little molecules like what's found in the 25-NB or FLY families, or something like MDMB-CHMNACA. If it ain't broke, don't fix it. Our algorithmic and predictive power in pharmacology is one of the absolute worst out of all the sciences. The absolute state of this naive futurist mindset that we can move fast in drug research is absolutely horrifying to even suggest. That's not where the state of the art is, and I'd put big money on us not getting there for another 100k years or so.
I don't think it's (just) encountering the profound that ends addiction, I think it really just alters or "resets" your brain structure. I know somebody who had bit their nails for their entire life well into their 30's and after a mega dose of mushrooms they just stopped. It wasn't a shift in perspective, they just didn't have that habit anymore, or even the thought of it. They didn't even notice they stopped biting their nails until they had trouble typing.
It also seems to alleviate nerve pain, and apparently enabled one man paralyzed below the waist to walk again. Something really fundamental is getting altered.
Relevant:
https://www.theguardian.com/science/2026/may/05/magic-mushro...
Also
https://www.outsideonline.com/outdoor-adventure/exploration-...
I would advice against a too high of a dose first time. The 5 grams they normally give in studies seems to be on the high side for a first time.
Around a week later I took the same dose again (the rest of what I had) to help process the trauma. (It did help. I of course avoided the situation that made me faint the first time)
I'd want to try psilocybin again sometime; it's quite a bit more expensive than LSD but it does have an interesting profile (for me: less stimulant-like)
It can also just be easy for some proponents to forget that tonnes of people do and have done these things, with no clear significant lasting effects. And it is also common even for enthusiasts to say they they need to do take trips somewhat regularly (e.g. every few weeks or months) to regain the benefits. One-off miracles obviously happen, but I think are statistically likely the exception. And you can reverse or reject your insights, so for sure the trip is only one piece of the puzzle.
I'd love to see more serious research on psychedelics in general, to better engineer for useful and changing experiences. As it stands, just "take the psychedelic, manage your set and setting, and you'll have a significant positive effect" is generally not very plausible nor I think actually supported empirically or even by most anecdotes.
Front. Neurosci., 28 May 2026
Sec. Neuropharmacology
Volume 20 - 2026 | https://doi.org/10.3389/fnins.2026.1813281
Background:
Advanced Alzheimer’s disease (AD) is generally regarded as a stage of irreversible functional decline. Psilocybin is known to transiently alter large-scale brain network dynamics and to induce plasticity-related mechanisms in preclinical models, yet clinical data in advanced dementia remain lacking.
Case presentation:
We report the case of an octogenarian Japanese-American woman with a 10-year history of Alzheimer’s disease, including 5 years of marked hypofunction and predominantly monosyllabic speech. Baseline features included chronic urinary incontinence, executive dysfunction, dysphagia, dependent mobility, flat affect, and severe reduction in spontaneous communication. The patient received 5 g of orally administered psilocybin-containing mushrooms (Enigma strain). The acute phase was marked by autonomic activation, clinically suspected hyperthermia, profuse sweating, and a prolonged deep sleep-like state. Approximately 19 h post-administration, spontaneous autobiographical speech emerged. Over subsequent days and weeks, functional improvements included restoration of urinary continence, improved ambulation, autonomous dressing, increased emotional responsiveness, sustained social interaction, contextual memory retrieval, preserved working memory for social context, and spontaneous conversational engagement.
Conclusion:
This case documents transient multidomain functional improvement in advanced Alzheimer’s disease following psilocybin administration. The findings do not imply disease reversal but suggest that residual functional capacity may persist in late-stage neurodegeneration and may become transiently accessible under specific neuromodulatory conditions.
Advanced Alzheimer’s disease imposes profound loss of autonomy, communication, continence, mobility, and social interaction, generating severe emotional and caregiving burden. Current therapeutic strategies at this stage are largely supportive, and meaningful functional recovery is generally considered unlikely. The global burden of Alzheimer’s disease and related dementias remains substantial, with major consequences for patients, families, caregivers, and health systems (). This clinical reality has motivated growing interest in neuromodulatory and neuroplasticity-oriented approaches capable of transiently restoring residual network function.
Psilocybin produces marked alterations in large-scale brain dynamics through serotonin 5-HT2A receptor activation. Human neuroimaging studies have shown altered default mode network integrity, reduced network segregation, and broad changes in functional connectivity after psilocybin administration (; ; ; ). Preclinical studies further suggest that serotonergic psychedelics can promote structural and functional plasticity, including dendritic growth and synaptic remodeling ().
Clinical investigation of psilocybin has focused primarily on psychiatric disorders and, more recently, on depression and anxiety in individuals with mild cognitive impairment or early Alzheimer’s disease. Published clinical data in advanced dementia remain extremely limited (). This report describes a case of transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration.
The patient was an octogenarian Japanese-American woman who lived with continuous family supervision and caregiver support. Progressive cognitive and functional decline had evolved over approximately 10 years. During the preceding 5 years, verbal output became predominantly monosyllabic, accompanied by severe reduction in spontaneous interaction, chronic urinary incontinence, executive dysfunction, impaired mobility, dysphagia, and marked dependence in activities of daily living.
Baseline examination revealed marked hypofunction, flat affect, reduced spontaneous verbal output, prolonged somnolence, impaired executive behavior, dependent ambulation, dysphagia, urinary incontinence, and severe reduction in social reciprocity and emotional expressiveness.
The diagnosis of advanced Alzheimer’s disease had been established clinically approximately 10 years prior to intervention. The longitudinal progressive neurodegenerative course, profound episodic memory impairment, language reduction, executive dysfunction, and functional decline were considered clinically most compatible with advanced Alzheimer’s disease.
Although the clinical course was considered most consistent with advanced Alzheimer’s disease, formal biomarker confirmation and advanced neuroimaging were not available in the present real-world setting. Therefore, mixed or alternative neurodegenerative contributions, including vascular components, cannot be fully excluded. No evidence suggesting acute delirium, intoxication, or an alternative acute neurological diagnosis was identified during the observation period.
A single oral dose of 5 g of psilocybin-containing mushrooms (Enigma strain) was administered during the initial intervention. One month later, a second supervised session using 3 g of psilocybin-containing mushrooms was performed due to persistence of clinically meaningful improvements, including sustained urinary continence.
The intervention was exploratory and observational in nature, as no established psilocybin dosing framework currently exists for advanced dementia. The selected mushroom dose was relatively high compared with dosing approaches commonly used in modern clinical trials and was chosen based on prior experiential observations regarding depth and duration of psychedelic-induced neurobehavioral effects.
The acute phase of the first session was characterized by clinically suspected hyperthermia, profuse sweating, profound somnolence, and a prolonged deep sleep-like state. Exact quantitative temperature measurements were not available. Approximately 19 h after administration, the patient spontaneously initiated autobiographical conversation lasting several hours.
During the second session, the patient remained significantly more verbally expressive throughout the experience and described emotionally positive imagery involving surfing with her son on a peaceful island. Facial expressivity, emotional reciprocity, spontaneous humor, and gait agility appeared markedly improved.
No severe persistent adverse effects, prolonged agitation, clinically significant cardiovascular instability, persistent psychotic symptoms, delayed neurological deterioration, or delayed medical complications were observed during follow-up.
Several clinically meaningful improvements persisted for weeks following the first intervention, including restoration of urinary continence, improved mobility, enhanced emotional reciprocity, increased spontaneous communication, and improved contextual social interaction (Table 1).
Table 1
| Time post-intervention | Domain | Clinical observation |
|---|---|---|
| 0–12 h | Autonomic/sleep | Clinically suspected hyperthermia, profuse sweating, prolonged deep sleep-like state |
| ~19 h (03:30) | Language/autobiographical memory | Spontaneous awakening, ~4 h of autobiographical speech |
| Day 1 | Alertness/social | Increased alertness, recognition of family |
| Day 2 | Motor | Independent ambulation |
| Days 2–3 | Executive/autonomy | Dressing self, spontaneous initiative |
| Days 2–3 | Continence | Dry diapers, including nighttime |
| Days 6–7 | Working memory/episodic | “Where did Celso go?”, correct vehicle recognition |
| Days 6–7 | Attention/affective | Sustained eye contact, reciprocal smiling |
Timeline of functional gains post-intervention.
Acute autonomic activation and a prolonged deep sleep-like state were followed by spontaneous autobiographical speech approximately 19 h post-administration and progressive recovery across motor, executive, continence, memory, and social-affective domains over subsequent days and weeks.
One month after the initial session, the patient remained continent and functionally improved compared with baseline. A second supervised psilocybin session using 3 g was subsequently performed and was associated with greater verbal expressivity, improved facial mimicry, spontaneous humor, emotionally valenced autobiographical imagery, and increased agility while walking.
The patient spontaneously stated: “It is pleasant to come here.”
Due to advanced cognitive impairment, formal structured self-report was limited. Nevertheless, during follow-up the patient spontaneously expressed emotionally positive statements regarding the sessions, including “It is pleasant to come here,” accompanied by increased emotional expressivity and autobiographical communication.
Observed gains were objective across autonomic, motor, executive, memory, affective, and social domains. The persistence of urinary continence after more than 5 years of chronic incontinence is particularly notable, given that continence depends on integrated interoceptive awareness, executive inhibition, and fronto-insular network function.
Recent human studies investigating psilocybin and sleep architecture have shown heterogeneous findings. In healthy volunteers, oral psilocybin increased REM sleep latency without major alterations in overall sleep–wake states (). In contrast, clinical reports in depression have described improvements in sleep disturbances following psilocybin administration (). The prolonged deep sleep-like state observed in the present patient may therefore reflect interactions between psilocybin-induced network modulation and altered baseline neurophysiology characteristic of advanced Alzheimer’s disease.
Beyond structural neuroplasticity, recent studies demonstrate marked reorganization of large-scale brain networks following psilocybin administration, including increased global integration, cortical desynchronization, and transient desegregation of canonical cortical systems (; ; ; ). Such findings support the hypothesis that psilocybin may transiently facilitate functional reintegration of residual neural systems in neurodegenerative disease.
The present report has important limitations, including the single-case design, absence of formal polysomnographic monitoring, quantitative electrophysiology, neuroimaging biomarkers, and standardized cognitive scales. Causality cannot be established, and spontaneous fluctuations inherent to neurodegenerative disease cannot be completely excluded.
Importantly, mechanistic interpretations remain speculative. The present report should be understood primarily as a detailed observational description intended to generate hypotheses for future controlled investigation. The findings should not be interpreted as reversal of Alzheimer’s pathology. Rather, they raise the possibility that latent functional capacities may persist in advanced neurodegeneration and become temporarily accessible under specific neuromodulatory conditions.
Residual functional capacity may persist in advanced Alzheimer’s disease and may become transiently accessible following psilocybin-induced modulation of large-scale brain networks. Systematic investigation is warranted.
The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.
Ethical approval was not required for this single case report conducted in routine private clinical practice, in accordance with local legislation and institutional requirements. No experimental protocol or prospective research procedures were conducted. Written informed consent was obtained from the patient’s legal guardian for the publication of this case report.
ML: Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing. MC: Supervision, Validation, Writing – review & editing. JS: Supervision, Validation, Writing – review & editing.
The author(s) declared that financial support was not received for this work and/or its publication.
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that Generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
1
Alzheimer's Association (2024). 2024 Alzheimer's disease facts and figures. _Alzheimers Dement._20, 3708–3821. doi: 10.1002/alz.13809,
2
Carhart-HarrisR. L.ErritzoeD.WilliamsT.StoneJ. M.ReedL. J.ColasantiA.et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. _Proc. Natl. Acad. Sci. USA_109, 2138–2143. doi: 10.1073/pnas.1119598109,
3
DudysovaD.JankuK.SmotekM.SaifutdinovaE.KoprivovaJ.BuskovaJ.et al. (2020). The effects of daytime psilocybin administration on sleep: implications for antidepressant action. _Front. Pharmacol._11:602590. doi: 10.3389/fphar.2020.602590,
4
LyC.GrebA. C.CameronL. P.WongJ. M.BarraganE. V.WilsonP. C.et al. (2018). Psychedelics promote structural and functional neural plasticity. _Cell Rep._23, 3170–3182. doi: 10.1016/j.celrep.2018.05.022,
5
MadsenM. K.FisherP. M.BurmesterD.DyssegaardA.StenbaekD. S.KristiansenS.et al. (2021). Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. _Eur. Neuropsychopharmacol._50, 121–132. doi: 10.1016/j.euroneuro.2021.06.001,
6
ReidM. J.KettnerH.BlankenT. F.WeissB.Carhart-HarrisR. (2024). Preliminary evidence of sleep improvements following psilocybin administration and their involvement in antidepressant therapeutic action. _Curr. Psychiatry Rep._26, 659–669. doi: 10.1007/s11920-024-01529-2,
7
SiegelJ. S.SubramanianS.PerryD.KayB. P.GordonE. M.LaumannT. O.et al. (2024). Psilocybin desynchronizes the human brain. _Nature_632, 131–138. doi: 10.1038/s41586-024-07624-5,
8
SilversteinB. H.KolbmanN.NelsonA.LiuT.GuzzoP.GilliganJ.et al. (2025). Intravenous psilocybin induces dose-dependent changes in functional network organization in rat cortex. _Transl. Psychiatry_15:93. doi: 10.1038/s41398-025-03308-4,
9
Vann JonesS. A.O'KellyA. (2020). Psychedelics as a treatment for Alzheimer's disease dementia. _Front. Synaptic. Neurosci._12:34. doi: 10.3389/fnsyn.2020.00034,
10
ZhengS.MaR.YangY.LiG. (2024). Psilocybin for the treatment of Alzheimer's disease. _Front. Neurosci._18:1420601. doi: 10.3389/fnins.2024.1420601,
Keywords
advanced dementia, Alzheimer’s disease, functional recovery, neuroplasticity, psilocybin
Citation
Lago M, Cerveira M and Simonet JX (2026) Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report. Front. Neurosci. 20:1813281. doi: 10.3389/fnins.2026.1813281
Received
18 February 2026
Revised
07 May 2026
Accepted
11 May 2026
Published
28 May 2026
Volume
20 - 2026
Updates
Copyright
© 2026 Lago, Cerveira and Simonet.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*****Correspondence: Marcos Lago, ml@marcoslago.com.br
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.